Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Deraco

Showing results (61-70 of 178) with videos related to

Pageof 18
Sort By:
In Vivo (Athens, Greece)|January 6, 2007
Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single centerMarcello Deraco, Shigeki Kusamura, Barbara Laterza, et al.
World Journal of Gastrointestinal Oncology|December 17, 2010
Pathophysiology and biology of peritoneal carcinomatosisShigeki Kusamura, Dario Baratti, Nadia Zaffaroni, et al.
Annals of Surgical Oncology|May 19, 2007
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapyDario Baratti, Shigeki Kusamura, Antonia Martinetti, et al.
Annals of Surgical Oncology|April 9, 2004
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritoneiMarcello Deraco, Dario Baratti, Maria Grazia Inglese, et al.
Annals of Surgical Oncology|December 8, 2006
Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusionDario Baratti, Shigeki Kusamura, Antonia Martinetti, et al.
BJS Open|August 12, 2025
Predicting postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: retrospective cohort studyLorena Martin-Roman, Shigeki Kusamura, Marcello Guaglio, et al.
Journal of Surgical Oncology|June 27, 2003
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusionMarcello Deraco, Paolo Casali, M G Inglese, et al.
Tumori|June 25, 2010
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infectionMaria Rosaria Balestra, Dario Baratti, Fulvio Crippa, et al.
Annals of Surgical Oncology|September 12, 2022
Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and OutcomesDario Baratti, Shigeki Kusamura, Marcello Guaglio, et al.
Journal of Hematology & Oncology|January 20, 2017
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanismRihan El Bezawy, Michelandrea De Cesare, Marzia Pennati, et al.
Pageof 18

Showing results (61-70 of 178) with videos related to

Sort By:
Pageof 18
In Vivo (Athens, Greece)|January 6, 2007
Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single centerMarcello Deraco, Shigeki Kusamura, Barbara Laterza, et al.
World Journal of Gastrointestinal Oncology|December 17, 2010
Pathophysiology and biology of peritoneal carcinomatosisShigeki Kusamura, Dario Baratti, Nadia Zaffaroni, et al.
Annals of Surgical Oncology|May 19, 2007
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapyDario Baratti, Shigeki Kusamura, Antonia Martinetti, et al.
Annals of Surgical Oncology|April 9, 2004
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritoneiMarcello Deraco, Dario Baratti, Maria Grazia Inglese, et al.
Annals of Surgical Oncology|December 8, 2006
Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusionDario Baratti, Shigeki Kusamura, Antonia Martinetti, et al.
BJS Open|August 12, 2025
Predicting postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: retrospective cohort studyLorena Martin-Roman, Shigeki Kusamura, Marcello Guaglio, et al.
Journal of Surgical Oncology|June 27, 2003
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusionMarcello Deraco, Paolo Casali, M G Inglese, et al.
Tumori|June 25, 2010
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infectionMaria Rosaria Balestra, Dario Baratti, Fulvio Crippa, et al.
Annals of Surgical Oncology|September 12, 2022
Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and OutcomesDario Baratti, Shigeki Kusamura, Marcello Guaglio, et al.
Journal of Hematology & Oncology|January 20, 2017
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanismRihan El Bezawy, Michelandrea De Cesare, Marzia Pennati, et al.
Pageof 18